glp1InjectablePrescription only (US)
SemaglutideBenefits, Dosage & Interactions
Also known as: ozempic, wegovy
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that belongs to the incretin mimetic class of medications. It is approved for the treatment of type 2 diabetes mellitus and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
~168 h
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Semaglutide in the cited sources. Published ranges are not dosing advice.
Semaglutide compared with similar compounds
| Attribute | Semaglutide | Tirzepatide | Retatrutide | Liraglutide |
|---|---|---|---|---|
| Class | GLP-1 receptor agonist | GIP/GLP-1 dual receptor agonist | GIP/GLP-1/glucagon triple agonist | GLP-1 receptor agonist |
| Route | Subcutaneous once weekly | Subcutaneous once weekly | Subcutaneous once weekly | Subcutaneous once daily |
| Half-life | ~7 days | ~5 days | ~6 days | ~13 hours |
| Evidence grade | Strong | Strong | Moderate | Strong |
| Oral stability | Oral tablet form exists (with SNAC absorption enhancer) | Not orally available | Not orally available | Not orally available |
| Typical published cycle | Ongoing while prescribed | Ongoing while prescribed | Investigational — phase 3 ongoing | Ongoing while prescribed |
| Main studied use | Type 2 diabetes and weight management | Type 2 diabetes and obesity | Obesity (investigational) | Type 2 diabetes and weight management |
References & evidence
Documents the Semaglutide entry is written from. Each number matches an inline marker above.
- [1]Once-Weekly Semaglutide in Adults with Overweight or ObesityWilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine · 2021 · Peer-reviewed · PMID 33567185
- [2]Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesMarso SP, Bain SC, Consoli A, et al. · New England Journal of Medicine · 2016 · Peer-reviewed · PMID 27633186
How to track Semaglutide doses
Semaglutide is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Semaglutide is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Semaglutide comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 168 h, effects and timing shifts show up over days rather than instantly. Review Semaglutide alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Semaglutide dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Semaglutide studied for?
What is Semaglutide?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that belongs to the incretin mimetic class of medications. It is approved for the treatment of type 2 diabetes mellitus and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Semaglutide is a synthetic analog of the naturally occurring human GLP-1 hormone, which plays a crucial role in glucose metabolism and appetite regulation. Due to its longer half-life compared to native GLP-1, semaglutide is typically administered once weekly via subcutaneous injection.
First approved by the U.S. Food and Drug Administration (FDA) in 2017 for type 2 diabetes under the brand name Ozempic, its approval for chronic weight management came in 2021 under the brand name Wegovy. While the active pharmaceutical ingredient is the same, the approved indications and dosage strengths often differ between brands. It works by mimicking the effects of GLP-1, leading to multiple physiological responses that contribute to its therapeutic effects. Its use has expanded rapidly due to its efficacy in managing blood sugar and promoting significant weight loss.
What does the research say about Semaglutide?
Tap a section to expand.
Semaglutide acts as a GLP-1 receptor agonist, meaning it binds to and activates the GLP-1 receptors found in various tissues throughout the body, including the pancreas, brain, and gastrointestinal tract. This activation leads to several key physiological effects:
* **Glucose-dependent insulin secretion:** In response to elevated blood glucose levels, semaglutide stimulates pancreatic beta cells to release insulin. This effect is glucose-dependent, meaning it primarily occurs when blood sugar is high, reducing the risk of hypoglycemia when blood glucose is normal.
* **Suppression of glucagon secretion:** It inhibits the release of glucagon from pancreatic alpha cells, particularly after meals. Glucagon is a hormone that raises blood glucose, so its suppression helps to lower blood sugar levels.
* **Delayed gastric emptying:** Semaglutide slows down the rate at which food empties from the stomach. This contributes to a feeling of fullness and can reduce post-meal blood glucose spikes.
* **Central appetite regulation:** It acts on GLP-1 receptors in the brain, particularly in areas involved in appetite control, such as the hypothalamus. This interaction leads to reduced hunger, increased satiety (feeling of fullness), and decreased food cravings, which ultimately contributes to reduced caloric intake and weight loss. (Reference: FDA label for Ozempic, FDA label for Wegovy)
Semaglutide's therapeutic effects stem from these combined actions, resulting in improved glycemic control and significant reductions in body weight.
Source for this section: Sources for How does Semaglutide work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefits of semaglutide are related to its approved indications for type 2 diabetes and chronic weight management.
For individuals with type 2 diabetes:
* **Improved glycemic control:** Semaglutide effectively lowers HbA1c (a measure of average blood sugar over 2-3 months) and fasting plasma glucose levels. (Reference: American Diabetes Association, FDA label)
* **Cardiovascular risk reduction:** Studies have shown that semaglutide can reduce the risk of major adverse cardiovascular events (e.g., heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease. (Reference: NIH, FDA label)
* **Weight loss:** Many individuals with type 2 diabetes also experience weight loss with semaglutide, which can further contribute to improved metabolic health.
For individuals with obesity or overweight with at least one weight-related comorbidity (e.g., high blood pressure, high cholesterol):
* **Significant weight loss:** Clinical trials have demonstrated substantial and sustained weight loss (often 10-15% or more of initial body weight) compared to placebo. (Reference: NEJM, FDA label)
* **Improved metabolic markers:** Weight loss induced by semaglutide can lead to improvements in various cardiometabolic parameters, including blood pressure, lipid profiles, and insulin sensitivity. (Reference: NIH ODS, MedlinePlus)
These benefits underscore semaglutide's role as a multifaceted therapeutic agent in managing complex chronic conditions.
Extensive clinical trial data supports the efficacy and safety of semaglutide for both type 2 diabetes and chronic weight management. The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, independent of diabetes status. This landmark study was published in the *New England Journal of Medicine*.
For type 2 diabetes, the SUSTAIN clinical trial program provided robust evidence for semaglutide's superior glycemic control and weight loss compared to other antidiabetic medications and placebo. For example, SUSTAIN 6 showed cardiovascular safety and a reduction in major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk. (Reference: FDA label for Ozempic, American Diabetes Association Position Statement)
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program evaluated semaglutide's efficacy for weight management. STEP 1, published in the *New England Journal of Medicine*, reported an average weight loss of 14.9% with semaglutide compared to 2.4% with placebo over 68 weeks. Subsequent STEP trials further confirmed significant weight loss and improvements in cardiometabolic risk factors across various populations, including those with type 2 diabetes and those without. (Reference: FDA label for Wegovy, NIH Clinical Trials Database)
Regulatory bodies like the FDA and European Medicines Agency (EMA) have reviewed these comprehensive data sets to grant approvals for semaglutide's various indications, ensuring its use is based on rigorous scientific evidence.
Common side effects associated with semaglutide often include gastrointestinal issues, especially during the initial weeks of treatment as the body adjusts to the medication. These typically lessen over time.
Common side effects (occurring in 5% or more of patients):
* Nausea
* Vomiting
* Diarrhea
* Constipation
* Abdominal pain
* Dyspepsia (indigestion)
Less common but serious side effects can include:
* Pancreatitis (inflammation of the pancreas), characterized by severe abdominal pain that may radiate to the back and be accompanied by vomiting. (Reference: MedlinePlus, FDA label)
* Cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder).
* Hypoglycemia (low blood sugar) may occur, particularly when semaglutide is combined with other medications that lower blood sugar, such as insulin or sulfonylureas.
* Acute kidney injury or worsening of chronic kidney failure, especially in patients experiencing severe gastrointestinal adverse reactions leading to dehydration.
* Thyroid C-cell tumors: Semaglutide has been shown to cause thyroid C-cell tumors in rodents, but it is unknown whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans.
* Diabetic retinopathy complications: In patients with a history of diabetic retinopathy, there have been reports of temporary worsening of the condition, though the long-term clinical significance remains under investigation. (Reference: FDA label)
Patients should report any persistent or severe side effects to their healthcare provider. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several warnings and precautions are associated with the use of semaglutide, necessitating careful patient selection and monitoring.
* **Risk of Thyroid C-cell Tumors:** Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In rodents, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is unknown whether semaglutide causes MTC in humans. Patients should be counseled about the potential risk of MTC and symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). (Reference: FDA label)
* **Pancreatitis:** Acute pancreatitis has been reported in patients treated with GLP-1 receptor agonists, including semaglutide. Patients should be informed of the characteristic symptoms of acute pancreatitis (e.g., severe persistent abdominal pain, which may radiate to the back and be accompanied by vomiting) and discontinue semaglutide if pancreatitis is suspected. (Reference: MedlinePlus)
* **Diabetic Retinopathy Complications:** In patients with a history of diabetic retinopathy, there have been reports of worsening of diabetic retinopathy. Patients with diabetic retinopathy should be monitored for progression. (Reference: FDA label)
* **Hypoglycemia:** The risk of hypoglycemia is increased when semaglutide is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin. A dose reduction of the insulin secretagogue or insulin may be necessary. (Reference: American Diabetes Association, FDA label)
* **Acute Kidney Injury:** There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, including semaglutide. Some of these events were reported in patients without known underlying renal disease. Most of the reported events occurred in patients who experienced nausea, vomiting, or diarrhea leading to dehydration. (Reference: FDA label)
* **Gallbladder Problems:** Gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis) have been reported with GLP-1 receptor agonist use. (Reference: NIH ODS)
* **Gastrointestinal Effects:** Nausea, vomiting, and diarrhea are common, particularly when initiating treatment or increasing the dose. These can lead to dehydration and, in some cases, acute kidney injury.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Semaglutide is contraindicated in specific patient populations due to significant safety concerns.
* **Personal or family history of medullary thyroid carcinoma (MTC):** Due to the risk of thyroid C-cell tumors observed in animal studies, semaglutide should not be used in individuals with a personal or family history of MTC. (Reference: FDA label)
* **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2):** Patients with MEN 2 are also at an increased risk of MTC and should not use semaglutide. (Reference: FDA label)
* **Known hypersensitivity to semaglutide or any of its excipients:** This includes severe allergic reactions such as anaphylaxis or angioedema observed with previous exposure. (Reference: FDA label)
* **Diabetic ketoacidosis:** Semaglutide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it is not a substitute for insulin. (Reference: American Diabetes Association)
It is crucial for clinicians to screen patients for these conditions before initiating semaglutide therapy. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Caution should be exercised when combining semaglutide with certain medications or classes of drugs, as interactions can affect efficacy or increase the risk of adverse events.
* **Insulin secretagogues (e.g., sulfonylureas) and Insulin:** Concomitant use with insulin or an insulin secretagogue significantly increases the risk of hypoglycemia. If co-administered, a dose reduction of the sulfonylurea or insulin may be required. Close monitoring of blood glucose levels is essential. (Reference: FDA label)
* **Oral Medications:** Semaglutide delays gastric emptying, which can potentially affect the absorption of concomitantly administered oral medications. Patients taking oral medications that require rapid gastrointestinal absorption or have a narrow therapeutic index should be monitored closely. For example, the effectiveness of oral contraceptives may theoretically be reduced, though clinical studies have not shown this to be a significant issue. Nonetheless, prescribers often recommend taking oral medications at a different time from the semaglutide injection or monitoring for clinical effects. (Reference: FDA label)
* **Other GLP-1 Receptor Agonists:** Semaglutide should not be used with other GLP-1 receptor agonists, as this would increase the risk of side effects without providing additional therapeutic benefit due to overlapping mechanisms of action. (Reference: DrugBank)
Always discuss all current medications, including over-the-counter drugs, supplements, and herbal products, with a healthcare professional before starting semaglutide. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Semaglutide is a once-weekly subcutaneous injection. The typical timing recommendation is to administer the injection on the same day each week, at any time of day, with or without meals. Injecting on the same day weekly helps maintain consistent GLP-1 receptor activation and therapeutic levels of the medication.
If a dose is missed, it should be administered as soon as possible, within 5 days of the regularly scheduled dose. If more than 5 days have passed since the missed dose, the missed dose should be skipped, and the next dose administered on the regularly scheduled day. This helps to avoid unintended double dosing or accumulation. (Reference: FDA label for Ozempic, FDA label for Wegovy)
It is important to follow the specific instructions provided by the prescribing clinician or product labeling, and to consider lifestyle factors such as personal schedule to ensure adherence to the once-weekly regimen.
Source for this section: Sources for When should you take Semaglutide?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Semaglutide?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| MK-677 | Note | Compound pairConfidence: theoretical | MK-677 raises IGF-1 and can transiently raise glucose; GLP-1 helps.Source pending | Monitor glucose; combine only with clinician oversight. |
| Insulin (Rapid) | Caution | Compound pairConfidence: theoretical | Combining a GLP-1 with rapid insulin increases hypoglycemia risk.Source pending | Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely. |
| Insulin (Long-Acting) | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
Frequently asked questions about Semaglutide
Semaglutide aids weight loss by mimicking a natural hormone called GLP-1, which influences areas of the brain that regulate appetite, leading to reduced hunger and increased feelings of fullness. It also slows gastric emptying, further contributing to satiety and reduced caloric intake. (Reference: NIH ODS)
No, semaglutide is not insulin. It is a GLP-1 receptor agonist. While it helps lower blood sugar by stimulating insulin release in a glucose-dependent manner and reducing glucagon, it does not replace the need for insulin in individuals who are insulin deficient, such as those with type 1 diabetes. (Reference: American Diabetes Association)
While some effects, such as a reduction in appetite, may be noticed relatively quickly, the full therapeutic benefits, particularly for blood sugar control and significant weight loss, accumulate gradually over several weeks and months as the dose is typically escalated. (Reference: FDA label)
Semaglutide is not suitable for everyone. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It also has other contraindications and warnings, and its use requires a prescription and medical evaluation. (Reference: FDA label)
If you miss a dose of semaglutide, take it as soon as you remember, provided it is within 5 days of the regularly scheduled dose. If more than 5 days have passed, skip the missed dose and resume your regular dosing schedule with the next planned injection. Do not take two doses at once to make up for a missed dose. (Reference: FDA label)
Semaglutide is a supplement, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 168 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Semaglutide with no sign-up.
Combining a supplement like Semaglutide with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Semaglutide: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A long plasma half-life of about 168 hours means Semaglutide is commonly dosed every few days or weekly rather than daily. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
For an injectable like Semaglutide the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Semaglutide?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity(opens PubMed in a new tab)N Engl J Med · 2021 · PMID 33567185 · https://pubmed.ncbi.nlm.nih.gov/33567185/
- 2.Tirzepatide as Compared with Semaglutide for the Treatment of Obesity(opens PubMed in a new tab)N Engl J Med · 2025 · PMID 40353578 · https://pubmed.ncbi.nlm.nih.gov/40353578/
- 3.Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension(opens PubMed in a new tab)Diabetes Obes Metab · 2022 · PMID 35441470 · https://pubmed.ncbi.nlm.nih.gov/35441470/
- 4.Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial(opens PubMed in a new tab)Lancet · 2021 · PMID 33667417 · https://pubmed.ncbi.nlm.nih.gov/33667417/
- 5.Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes(opens PubMed in a new tab)N Engl J Med · 2023 · PMID 37952131 · https://pubmed.ncbi.nlm.nih.gov/37952131/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 56843331(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/56843331
Verify at
Publisher search links for Semaglutide. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Clinical practice guidelines (PubMed)(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Semaglutide?
Plain-text summary, safe to quote verbatim:
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that belongs to the incretin mimetic class of medications. It is approved for the treatment of type 2 diabetes mellitus and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
Source: DoseRoutine — https://doseroutine.com/library/semaglutide
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Semaglutide — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/semaglutide
What compounds are similar to Semaglutide?
Others in the glp1 category or studied for the same goals.
Which goals is Semaglutide used for?
Other compounds studied for the same benefits as Semaglutide.
Continue exploring
See every compound DoseRoutine catalogs for these goals.